Navegar por autor "Pego Reigosa, José María"

A look at lofgren syndrome: 80 cases in two universitary hospitals

2014- Pego Reigosa, José María; Carnicero Iglesias, Maria

ANALYSIS OF DISEASE ACTIVITY AND RESPONSE TO TREATMENT IN A LARGE COHORT FROM THE SPANISH SOCIETY OF RHEUMATOLOGY REGISTRY OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (RELESSER)

2014- Pego Reigosa, José María; Del Campo Pérez, Victor; Mouriño Rodriguez, Coral

Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus

2015- Freire Gonzalez, Mercedes; del Campo Pérez, Victor Miguel; Pego Reigosa, José María

Analysis of the implementation of an innovative IT solution to improve waiting times, communication with primary care and efficiency in Rheumatology

2022- Pego Reigosa, José María; Peña Gil, Carlos; Rodríguez Lorenzo, David; Altabas Gonzalez, Irene; Pérez Gómez, Nair; [et al.]

Angiopoietin-2 Promotes Inflammatory Activation in Monocytes of Systemic Sclerosis Patients

2020- Carvalheiro, T.; Lopes, A. P.; van der Kroef, M.; Malvar-Fernandez, B.; Rafael-Vidal, C.; [et al.]

Bacteremia in Systemic Lupus Erythematosus in Patients from a Spanish Registry: Risk Factors, Clinical and Microbiological Characteristics, and Outcomes

2020- Rúa-Figueroa, Iñigo; López-Longo, Francisco J; Del Campo, Víctor; Galindo-Izquierdo, María; Uriarte, Esther; [et al.]

Biological therapy for systemic vasculitis: a systematic review

2014- Pego Reigosa, José María

Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases

2020- Rafael-Vidal, C.; Pérez Gómez, Nair; Altabás, I.; Garcia, S.; Pego Reigosa, José María [et al.]

Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis

2021- Vidal Pérez, Rafael Carlos; Altabas Gonzalez, Irene; Pérez Gómez, Nair; Mouriño Rodriguez, Coral; Pego Reigosa, José María; [et al.]

Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort

2019- Tejera Segura, B.; Rua-Figueroa, I.; Pego Reigosa, José María; del Campo Pérez, Victor Miguel; Wincup, C.; [et al.]

Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-Life, International Systemic Lupus Erythematosus Cohort

2015- Pego Reigosa, José María

Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies

2020- Sanchez-Piedra, C.; Diaz-Torne, C.; Manero, J.; Pego Reigosa, José María; Rua-Figueroa, I.; [et al.]

Comment on: Comorbidities (excluding lymphoma) in Sjögren's syndrome. Reply

2021- Pego Reigosa, José María; Rúa-Figueroa Fernández de Larrinoa, Í

Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences

2015- Freire Gonzalez, Mercedes; Rodríguez Gómez, Manuel; Vázquez Rodríguez, Tomás Ramón; Pego Reigosa, José María; Quevedo Vila, Victor [et al.]

Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico

2013- Gómez-Reino Carnota, Juan Jesús; Pego Reigosa, José María

Cumulative incidence, associated factors and clinical impact of severe infections in a cohort of over 3,500 patients with Systemic Lupus Erythematosus.

2014- Pego Reigosa, José María; Del Campo Pérez, Victor

Design of lupus impact tracker (lit) validation study in five european clinical practice settings

2013- Pego Reigosa, José María

Dipeptidyl Peptidase IV (DPP-IV, CD26) Levels In Patients With Rheumatoid Arthritis Treated With Biologic Therapies and Correlation With The Activity Of The Disease

2013- Pego Reigosa, José María; Del Campo Pérez, Victor; Aspe De la Iglesia, Bruno; Viñuela Roldán, Juan; Mouriño Rodriguez, Coral; [et al.]

Dyslipoproteinemia and its relation with the activity of the disease and its treatment in a large spanish multicentric lupus cohort

2012- Pego Reigosa, José María

Efficacy and Safety of Disease Modifying Drugs, Biologic Therapies and Immunoglobulin in Patients with Polymyositis and Dermatomyositis: A Systematic Literature Review

2012- Pego Reigosa, José María

Repositorio digital RUNA

Navegar por autor "Pego Reigosa, José María"

A look at lofgren syndrome: 80 cases in two universitary hospitals ﻿

ANALYSIS OF DISEASE ACTIVITY AND RESPONSE TO TREATMENT IN A LARGE COHORT FROM THE SPANISH SOCIETY OF RHEUMATOLOGY REGISTRY OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (RELESSER) ﻿

Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus ﻿

Analysis of the implementation of an innovative IT solution to improve waiting times, communication with primary care and efficiency in Rheumatology ﻿

Angiopoietin-2 Promotes Inflammatory Activation in Monocytes of Systemic Sclerosis Patients ﻿

Bacteremia in Systemic Lupus Erythematosus in Patients from a Spanish Registry: Risk Factors, Clinical and Microbiological Characteristics, and Outcomes ﻿

Biological therapy for systemic vasculitis: a systematic review ﻿

Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases ﻿

Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis ﻿

Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort ﻿

Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-Life, International Systemic Lupus Erythematosus Cohort ﻿

Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies ﻿

Comment on: Comorbidities (excluding lymphoma) in Sjögren's syndrome. Reply ﻿

Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences ﻿

Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico ﻿

Cumulative incidence, associated factors and clinical impact of severe infections in a cohort of over 3,500 patients with Systemic Lupus Erythematosus. ﻿

Design of lupus impact tracker (lit) validation study in five european clinical practice settings ﻿

Dipeptidyl Peptidase IV (DPP-IV, CD26) Levels In Patients With Rheumatoid Arthritis Treated With Biologic Therapies and Correlation With The Activity Of The Disease ﻿

Dyslipoproteinemia and its relation with the activity of the disease and its treatment in a large spanish multicentric lupus cohort ﻿

Efficacy and Safety of Disease Modifying Drugs, Biologic Therapies and Immunoglobulin in Patients with Polymyositis and Dermatomyositis: A Systematic Literature Review ﻿

A look at lofgren syndrome: 80 cases in two universitary hospitals

ANALYSIS OF DISEASE ACTIVITY AND RESPONSE TO TREATMENT IN A LARGE COHORT FROM THE SPANISH SOCIETY OF RHEUMATOLOGY REGISTRY OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (RELESSER)

Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus

Analysis of the implementation of an innovative IT solution to improve waiting times, communication with primary care and efficiency in Rheumatology

Angiopoietin-2 Promotes Inflammatory Activation in Monocytes of Systemic Sclerosis Patients

Bacteremia in Systemic Lupus Erythematosus in Patients from a Spanish Registry: Risk Factors, Clinical and Microbiological Characteristics, and Outcomes

Biological therapy for systemic vasculitis: a systematic review

Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases

Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis

Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort

Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-Life, International Systemic Lupus Erythematosus Cohort

Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies

Comment on: Comorbidities (excluding lymphoma) in Sjögren's syndrome. Reply

Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences

Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico

Cumulative incidence, associated factors and clinical impact of severe infections in a cohort of over 3,500 patients with Systemic Lupus Erythematosus.

Design of lupus impact tracker (lit) validation study in five european clinical practice settings

Dipeptidyl Peptidase IV (DPP-IV, CD26) Levels In Patients With Rheumatoid Arthritis Treated With Biologic Therapies and Correlation With The Activity Of The Disease

Dyslipoproteinemia and its relation with the activity of the disease and its treatment in a large spanish multicentric lupus cohort

Efficacy and Safety of Disease Modifying Drugs, Biologic Therapies and Immunoglobulin in Patients with Polymyositis and Dermatomyositis: A Systematic Literature Review